Form 4: enVVeno Medical Corp Director Acquires Stock Options

Matthew Jenusaitis, a director at enVVeno Medical Corp, was granted 19,752 stock options on December 18, 2024.

Summary

• Matthew Jenusaitis, a director of enVVeno Medical Corp, received 19,752 stock options on December 18, 2024.
• The options were granted under the company's Amended and Restated 2016 Omnibus Incentive Plan.
• The options have an exercise price of $2.57.
• The options vest in equal quarterly installments throughout the 2025 calendar year.
• The options expire on December 18, 2034.

Sentiment

Score: 7

Explanation: The document reflects a standard practice of granting stock options to a director, which is generally viewed positively as it aligns interests. There are no indications of negative sentiment.

Positives

• The grant of stock options to a director aligns their interests with the company's performance.
• The vesting schedule encourages long-term commitment from the director.

Future Outlook

The stock options will vest in equal quarterly installments throughout the 2025 calendar year.

Industry Context

Stock option grants are a common practice for incentivizing directors and aligning their interests with shareholders in the biotechnology and medical device industry.

Comparison to Industry Standards

• Stock option grants to directors are a standard practice across the industry, with vesting schedules typically ranging from 1 to 4 years.
• The exercise price of $2.57 is specific to enVVeno Medical Corp's stock price at the time of the grant.
• The 10-year expiration period is within the typical range for stock options.

Stakeholder Impact

• The stock option grant may positively impact shareholder confidence by aligning director interests with company performance.
• The vesting schedule may encourage long-term commitment from the director.

Key Dates

Keywords

stock options, director, insider trading, equity, incentive plan, vesting, enVVeno Medical Corp, NVNO